Introduction
Commonly people are talking about “peptides” to refer to a heterogeneous group of peptide medications or investigational compounds. These are increasingly promoted for injury recovery, tissue repair, performance and longevity, with BPC-157 attracting particular attention.
But what evidence supports the claims made about these compounds? How should animal studies, biological mechanisms and personal anecdotes be interpreted? What is currently known about their safety? And what do recent regulatory discussions actually mean for their medical status and availability?
In this episode, physician and Barbell Medicine founder Dr. Jordan Feigenbaum examines the evidence surrounding BPC-157 and other peptide medications, alongside the wider questions of risk, access and informed decision-making.
[00:13] What we want to address
[04:47] Interview start
[05:29] What do we mean by “peptides”?
[10:32] BPC-157 evidence
[16:49] Sourcing of peptides
[20:19] The gray zone of pro-peptide communication
[24:16] Risk sourcing vs drug effects
[26:25] FDA lists and compounding
[31:05] Risk tolerance and informed consent
[43:02] Why did pharma abandon peptide research?
[47:44] Harm reduction debate
[51:48] Practical takeaways
- [56:20] Key Ideas segment (Premium members only)
Episode Resources
- Join the Sigma newsletter for free
- Subscribe to Sigma Nutrition Premium
- Enroll in the next cohort of our Applied Nutrition Literacy course
- Barbell Medicine
- Instagram: jordan_barbellmedicine
- Book: Signal: What Testosterone Levels Are Telling You About Your Health
- Related episode: #524: Strength & Fitness Levels for Reducing Chronic Disease Risk & Promoting Health Ageing – Jordan Feigenbaum, MD
- Further reading:
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025.
- Ruenzi M, Stolte M, Veljaca M, et al. Efficacy and safety of PL 14736 (BPC 157) in patients with active ulcerative colitis. Gastroenterology. 2005. Meeting abstract; full study not published.
Guest Information
Dr. Jordan Feigenbaum is the founder of Barbell Medicine, a company that aims to promote health and successful aging by bringing the best of modern medicine together with strength, conditioning, and nutrition.
He is an experienced strength coach who also has his medical degree and residency training.
Study Notes
Overview
Peptides are short chains of amino acids, but the online phrase “peptides” usually refers to a heterogeneous group of peptide medications or investigational drugs. Some peptide medications, including insulin and glucagon-like peptide-1 receptor agonists, have well-characterised indications, dosing and safety profiles. BPC-157 belongs in a different category: it is an investigational compound promoted for injury recovery, tissue healing and other outcomes without a corresponding body of rigorous human clinical evidence.
The central issue is not whether BPC-157 is biologically active. Animal studies provide reasons to investigate it. The problem is that plausible mechanisms and favourable animal findings do not tell us whether the compound produces meaningful benefits in humans, which dose and route should be used, or what adverse effects may emerge with wider and longer use.
Useful Terminology
- Peptide: A chain of amino acids. The category includes naturally occurring peptides, food-derived peptides, supplements and established medications; it does not imply that all members have similar effects or risks.
- Peptide medication: A peptide used with the intention of preventing, diagnosing or treating disease, or altering a body function. Calling a compound a peptide does not lower the evidential standard required for a medication.
- BPC-157: A synthetic 15-amino-acid peptide, also described in the literature as PL 14736. It is promoted for tissue repair and other effects but remains investigational.
- Preclinical evidence: Evidence from laboratory or animal models. It can establish biological activity and support further research, but it cannot demonstrate clinical efficacy or adequately characterise human safety.
- Clinical efficacy: A beneficial effect demonstrated in people under controlled study conditions, ideally using randomisation, an appropriate comparator, prespecified outcomes and adequate follow-up.
- Safety profile: The type, frequency, severity and timing of adverse effects, together with information about dose, route, duration, interactions and susceptible populations.
- Compounding pharmacy: A pharmacy that prepares a medication for an identified clinical need. Compounding is not equivalent to regulatory approval of the active drug for efficacy and safety.
- Research chemical: A product sold nominally for laboratory use rather than approved human treatment. Labels such as “research use only” do not establish pharmaceutical identity, purity, sterility or dose accuracy.
- Informed consent: A decision based on a realistic account of expected benefits, known risks, important uncertainties and reasonable alternatives. When both benefits and risks are poorly characterised, consent is necessarily limited.
“Peptides” Is Too Broad to Be a Useful Clinical Category
- Chemical classification does not determine clinical value.
- Insulin, oxytocin, vasopressin analogues and GLP-1 receptor agonists are peptide medications, but each has its own target, indication, dose, route, evidence base and safety profile.
- Questions such as “Are peptides safe?” are therefore no more informative than asking